Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits th...
Main Authors: | Hideto Kameda, Miyuki Suzuki, Tsutomu Takeuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2007-01-01
|
Series: | Drug Target Insights |
Subjects: | |
Online Access: | http://la-press.com/article.php?article_id=451 |
Similar Items
-
by: Hideto Kameda, et al.
Published: (2007-01-01) -
Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis
by: Ji Ae Yang, et al.
Published: (2019-03-01) -
Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
by: Hideaki Yamakawa, et al.
Published: (2021-08-01) -
Lung involvement prevalence in patients with early rheumatoid arthritis without known pulmonary disease: a multicentric cross sectional study
by: Francisco Paulin, et al.
Published: (2021-08-01) -
Adipokines and Autoimmunity in Inflammatory Arthritis
by: Elena Neumann, et al.
Published: (2021-01-01)